http://purl.org/np/RAgxmbO2xX... RAgxmbO2xX

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-07-03T13:27:24.557Z

http://purl.org/np/RAgxmbO2xX... RAgxmbO2xX

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB08935 drugbank:DB08935

Leoni Bücken

2021-07-03T13:27:24.557Z

http://purl.org/np/RAgxmbO2xX... RAgxmbO2xX

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-07-03T13:27:24.557Z

http://purl.org/np/RAgxmbO2xX... RAgxmbO2xX

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-07-03T13:27:24.557Z

http://purl.org/np/RAgxmbO2xX... RAgxmbO2xX

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_1040 DOID_1040

Leoni Bücken

2021-07-03T13:27:24.557Z

http://purl.org/np/RAgxmbO2xX... RAgxmbO2xX

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-07-03T13:27:24.557Z

http://purl.org/np/RAgxmbO2xX... RAgxmbO2xX

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-07-03T13:27:24.557Z

http://purl.org/np/RAgxmbO2xX... RAgxmbO2xX

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

gazyva obinutuzumab is a cd2 directed cytolytic antibody and is indicated in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia 1 14 in combination with bendamustine followed by gazyva monotherapy for the treatment of patients with follicular lymphoma who relapsed after or are refractory to a rituximab containing regimen 1 14 in combination with chemotherapy followed by gazyva monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage ii bulky iii or iv follicular lymphoma 1 14 gazyva in combination with chlorambucil is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia see clinical studies 14 1 gazyva in combination with bendamustine followed by gazyva monotherapy is indicated for the treatment of patients with follicular lymphoma who relapsed after or are refractory to a rituximab containing regimen see clinical studies 14 2 gazyva in combination with chemotherapy followed by gazyva monotherapy in patients achieving at least a partial remission is indicated for the treatment of adult patients with previously untreated stage ii bulky iii or iv follicular lymphoma see clinical studies 14 2

Leoni Bücken

2021-07-03T13:27:24.557Z